

Title (en)  
METHOD FOR INDIVIDUALIZED DRUG THERAPY

Title (de)  
VERFAHREN FÜR INDIVIDUALISIERTE KREBSTHERAPIE

Title (fr)  
MÉTHODE POUR PHARMACOTHÉRAPIE INDIVIDUALISÉE

Publication  
**EP 3245602 A4 20180905 (EN)**

Application  
**EP 15878203 A 20150113**

Priority  
US 2015011148 W 20150113

Abstract (en)  
[origin: WO2016114761A1] Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (NSAID). Said methods comprise basing NSAID dose on each patient's pharmacokinetic and pharmacodynamic response to said NSAID.

IPC 8 full level  
**A61K 31/415** (2006.01); **A61K 31/60** (2006.01); **A61P 19/02** (2006.01); **A61P 29/00** (2006.01); **G16C 20/50** (2019.01); **G16H 20/10** (2018.01)

CPC (source: EP KR US)  
**A61K 9/0053** (2013.01 - KR); **A61K 31/415** (2013.01 - EP KR US); **A61K 31/4155** (2013.01 - KR); **A61K 31/5415** (2013.01 - KR);  
**A61K 31/616** (2013.01 - EP KR); **A61K 31/635** (2013.01 - EP KR); **A61K 45/06** (2013.01 - EP KR); **A61P 1/00** (2017.12 - EP);  
**A61P 3/00** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/00** (2017.12 - EP); **A61P 5/14** (2017.12 - EP);  
**A61P 7/00** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/06** (2017.12 - EP); **A61P 9/10** (2017.12 - EP);  
**A61P 9/12** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/12** (2017.12 - EP);  
**A61P 15/00** (2017.12 - EP); **A61P 15/14** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP KR); **A61P 19/08** (2017.12 - EP);  
**A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP);  
**A61P 25/06** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP);  
**A61P 25/22** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 27/16** (2017.12 - EP);  
**A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/08** (2017.12 - EP);  
**A61P 43/00** (2017.12 - EP); **G16C 20/50** (2019.01 - EP KR US); **G16C 99/00** (2019.01 - EP); **G16H 20/10** (2017.12 - EP US);  
**A61K 2300/00** (2013.01 - KR)

Citation (search report)  
• [X] US 2004087640 A1 20040506 - FERRO LEONARD J [US], et al  
• [I] HAMAMA AYMAN K ET AL: "Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography", JOURNAL OF CHROMATOGRAPHIC SCIENCE, OXFORD UNIVERSITY PRESS, CARY, NC, USA, vol. 43, no. 7, 31 July 2005 (2005-07-31), pages 351 - 354, XP009506965, ISSN: 0021-9665, Retrieved from the Internet <URL:https://epo.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwIV07T8MwELaABRbegvKSB1iQQp3Yjms2VCgMSCAoEkxWHCciqDRAqQT\_nru4aVVggM2RzpZzZ-vu870I2WfSpoxZHfCWIFQUgU243EgMhWrUFquGCY4P7RF91zdnlvLSZ3t7x58zZvp41v5DOqgKfiROuJVujSiBETmV\_djcAWGsu9WgCEHcSxrD-ZvK0zpoEkSk89wm7luKy3TWfrX\_pbJ4siYpCde-itkJuuvkv123cN> DOI: 10.1093/CHROMSCI/43.7.351  
• See references of WO 2016114761A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2016114761 A1 20160721**; AU 2015377253 A1 20170831; CA 2973569 A1 20160721; CN 107408147 A 20171128;  
EP 3245602 A1 20171122; EP 3245602 A4 20180905; JP 2018508476 A 20180329; KR 20160098029 A 20160818

DOCDB simple family (application)  
**US 2015011148 W 20150113**; AU 2015377253 A 20150113; CA 2973569 A 20150113; CN 20158007772 A 20150113;  
EP 15878203 A 20150113; JP 2017536310 A 20150113; KR 20157034125 A 20150113